

**IN THE CLAIMS:**

Claims 1, 2, 5, 7-11, 13, 14, 16, 27-49 and 51 are canceled herein. Claims 3, 4, 6, 12, 15, 17 and 50 have been amended herein. All of the pending claims are presented below. This listing of claims will replace all prior versions and listings of claims in the application. Please enter these claims as amended.

**Listing of Claims:**

1. & 2. (Canceled).
3. (Currently amended) ~~The A~~ human binding molecule ~~of claim 46, comprising an agonistic binding molecule capable of binding to and stimulating a human OX40-receptor, wherein the human binding molecule comprises a complementary determining region that comprises [[an]] the amino acid sequence selected from the group consisting of SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23 and SEQ ID NO:24.~~
4. (Currently amended) The human binding molecule of claim ~~[[46]]~~ 3, wherein the binding molecule comprises a heavy chain comprising an amino acid sequence ~~selected from the group consisting of SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27 and SEQ ID NO:28.~~
5. (Canceled).
6. (Currently amended) The human binding molecule of claim ~~[[46]]~~ 3, wherein the binding molecule comprises an immunoconjugate comprising at least one tag.
- 7.-11. (Canceled).

12. (Currently amended) A binding molecule capable of binding to and stimulating a human OX40-receptor, produced by a method comprising:

culturing under conditions conducive to the expression of the binding molecule a host comprising at least one vector encoding a binding molecule thereof able to bind to and stimulate the human OX40-receptor;

expressing the binding molecule; and

isolating the binding molecule,

wherein the binding molecule is a binding molecule according to claim 3.

13. & 14. (Canceled).

15. (Currently amended) A composition comprising the human binding molecule of claim [[46]] 3 and a stabilizing molecule.

16. (Canceled).

17. (Currently amended) A pharmaceutical composition comprising the human binding molecule of claim [[46]] 3 and at least one pharmaceutically acceptable excipient.

18. (Previously presented) The pharmaceutical composition of claim 17 further comprising at least one other therapeutic agent.

19. – 49. (Canceled).

50. (Currently amended) The human binding molecule of claim [[5]] 3, comprising SEQ ID NO:27 and SEQ ID NO:31.

51. (Canceled).